# İrfan Çiçin

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/irfan-cicin/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,008 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 40 |
| i10-index | 93 |
| Last Known Institution | Trakya University |
| OpenAlex ID | https://openalex.org/A5059941445 |
| ORCID iD | https://orcid.org/0000-0002-7584-3868 |
| Works | 308 |

## Researcher papers

- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407](https://scholariq.org/papers/a-randomized-placebo-controlled-trial-of-pembrolizumab-plus-chemotherapy-in/)
- [Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer](https://scholariq.org/papers/effect-of-first-line-serplulimab-vs-placebo-added-to-chemotherapy-on-survival-in/)
- [Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study](https://scholariq.org/papers/pembrolizumab-plus-ipilimumab-or-placebo-for-metastatic-non-small-cell-lung/)
- [Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer](https://scholariq.org/papers/ensartinib-vs-crizotinib-for-patients-with-anaplastic-lymphoma-kinase-positive/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-in-patients-with/)
- [Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial](https://scholariq.org/papers/telisotuzumab-vedotin-monotherapy-in-patients-with-previously-treated-c-met/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

## Researcher university

- [Trakya University](https://scholariq.org/institutions/trakya-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.